Financial News &amp; AI Sentiment Analysis

4 Reasons Johnson & Johnson Could Be the Perfect Stock to Own in Today's Turbulent Market

Johnson & Johnson is a healthcare giant that has shown remarkable resilience in turbulent markets. The company's diversified business, strong pipeline, and consistent dividend growth make it an attractive investment option in the current market environment.

GlobeNewswire Inc.

7 months ago

Neutral 50%

ONL Therapeutics Appoints Penny Fleck as Chief Development Officer

ONL Therapeutics, a clinical-stage biopharmaceutical company, has appointed Penny Fleck as its new Chief Development Officer. Fleck has over 20 years of experience leading R&D strategies at major pharmaceutical companies and will be responsible for advancing the company's lead asset, ONL1204 Ophthalmic Solution, towards a planned Phase 2 clinical study in geographic atrophy associated with age-related macular degeneration.

Confidence: 90%

GlobeNewswire Inc.

8 months ago

Johnson & Johnson submits application to the European Medicines Agency seeking approval of a new indication for IMBRUVICA® (ibrutinib) in adult patients with previously untreated mantle cell lymphoma (MCL) who are eligible for autologous stem cell transplant

Johnson & Johnson has submitted an application to the European Medicines Agency seeking approval for a new indication of its drug IMBRUVICA (ibrutinib) in the treatment of previously untreated mantle cell lymphoma in adult patients eligible for autologous stem cell transplant. The application is supported by data from the TRIANGLE study, which showed improved efficacy with ibrutinib-based regimens compared to the current standard of care.

GlobeNewswire Inc.

10 months ago

DARZALEX® (daratumumab)-SC based quadruplet regimen approved by the European Commission for patients with newly diagnosed multiple myeloma who are transplant-eligible

The European Commission has approved the use of a daratumumab-based quadruplet regimen for the treatment of newly diagnosed multiple myeloma patients who are eligible for autologous stem cell transplant. The regimen has shown significant improvements in progression-free survival, complete response rates, and minimal residual disease negativity compared to the current standard of care.

Benzinga

10 months ago

Positive 85%

Johnson & Johnson's Q3 Earnings: Revenue And EPS Beat On Strong Cancer Drug Sales, Revises Annual Outlook To Reflect V-Wave Acquisition

Johnson & Johnson reported strong Q3 earnings, with revenue and EPS beating estimates driven by strong cancer drug sales. The company revised its annual outlook to reflect the acquisition of V-Wave.

GlobeNewswire Inc.

11 months ago

CARVYKTI® ▼ (ciltacabtagene autoleucel ; cilta-cel) est la première thérapie cellulaire à augmenter de manière significative la survie globale par rapport aux thérapies standard chez les patients atteints d’UN myélome multiple dès le traitement de deuxième intention

CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) has significantly improved overall survival by 45% compared to standard therapies in patients with relapsed or refractory multiple myeloma, according to the Phase III CARTITUDE-4 study.